

## **ABSTRACT**

### **THE FINANCING STUDY OF THE USE OF ANTIBIOTIC LEVOFLOXACIN AND CEFOPERAZONE SULBACTAM IN CORONA PATIENTS VIRUS DISEASES-2019 MILD TO MODERATE**

**Dyah Ayu Listyaningrum**

*COVID-19 is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus-2. Antibiotics can be given as therapy in Covid-19 patients because it is confirmed that a secondary bacterial infection is present. The purpose of this study was to determine the cost of treatment related to the use of antibiotics Levofloxacin and Cefoperazone Sulbactam in mild to moderate Covid-19 patients at Bhayangkara H.S Samsueroi Mertojoso Hospital Surabaya. This study is a descriptive study with retrospective data collection February-April 2021 through patient medical and hospital information systems that collected 70 Covid-19 patient data. The data obtained from length of days of antibiotic use and length of hospitalization, cost of using antibiotics and the total cost of treatment. Covid-19 patients who received a mild degree of levofloxacin antibiotic therapy, the total cost of treatment was Rp. 66,648,632 with a length of hospitalization of 9 days and patients with moderate degrees a total cost of treatment Rp. 81,339,295 with 10 days of hospitalization. Patients who received a mild degree of antibiotic therapy with cefoperazone sulbactam, the total cost of treatment was Rp. 81.401.005 with a length of hospitalization of 11 days and patients with moderate degrees the total cost of treatment is Rp. 71,613,107 with 9 days of hospitalization.*

*Based on the results of this study, a cost evaluation in mild COVID-19 patients could be given the option of levofloxacin antibiotic therapy and moderate grade Covid-19 patients, the choice of antibiotic therapy cefoperazone sulbactam may be given due to lower costs and shorter length of hospitalization.*

**Keywords :** *Covid-19 , antibiotic, length of days of antibiotic use and of hospitalization, cost of using antibiotics and the total cost of treatment.*